down arrow

Checkpoint Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US1628282063
USD
4.26
0.03 (0.71%)

May 29

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.234.28

52 Week

2.164.50
Valuation
Technical
Day's Volume

CASH

8.67 M

Shareholding (Mar 2025)

FII

7.13%

Held by 21 FIIs

DII

87.01%

Held by 10 DIIs

Promoter

0.00%

How big is Checkpoint Therapeutics, Inc.?

22-Jun-2025

As of May 29, Checkpoint Therapeutics, Inc. has a market capitalization of 370.71 million, with net sales of 0.04 million and a net profit of -56.50 million over the last four quarters. The balance sheet as of December 2024 shows shareholder's funds of -12.62 million and total assets of 7.47 million.

As of May 29, Checkpoint Therapeutics, Inc. has a market capitalization of 370.71 million, categorizing it as a Micro Cap company.<BR><BR>As of the latest four quarters, the company reported net sales of 0.04 million and a net profit of -56.50 million.<BR><BR>As of December 2024, the balance sheet shows shareholder's funds of -12.62 million and total assets of 7.47 million.

Read More

What does Checkpoint Therapeutics, Inc. do?

22-Jun-2025

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company focused on developing immune-enhanced combination treatments for solid tumor cancers. It has a market cap of approximately $370.71 million and reported a net profit of -$11 million as of March 2025.

Overview:<BR>Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company focused on the development and commercialization of immune-enhanced combination treatments for solid tumor cancers, operating within the Pharmaceuticals: Major industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 370.71 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Dividend Yield: 23.88%<BR>Debt Equity: -2.03<BR>Return on Equity: -345.95%<BR>Price to Book: 22.75<BR><BR>Contact Details:<BR>Address: 2 Gansevoort St Fl 9, NEW YORK NY: 10014-1667<BR>Tel: 1 212 5544366<BR>Website: http://www.checkpointtx.com

Read More

Who are in the management team of Checkpoint Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Checkpoint Therapeutics, Inc. includes Chairman Michael Weiss, CEO James Oliviero, and several independent directors: Dr. Lindsay Rosenwald, Christian Bechon, Scott Boilen, Neil Herskowitz, and Barry Salzman. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Checkpoint Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Michael Weiss, Chairman of the Board<BR>- Mr. James Oliviero, President, Chief Executive Officer, and Director<BR>- Dr. Lindsay Rosenwald, Director<BR>- Mr. Christian Bechon, Independent Director<BR>- Mr. Scott Boilen, Independent Director<BR>- Mr. Neil Herskowitz, Independent Director<BR>- Mr. Barry Salzman, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Checkpoint Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of May 6, 2021, Checkpoint Therapeutics, Inc. is considered overvalued with a valuation downgrade to "does not qualify," despite a strong year-to-date return of 33.12%, while its long-term performance shows a significant decline of -79.91% over five years compared to the S&P 500's 96.61%.

As of 6 May 2021, the valuation grade for Checkpoint Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its high Price to Book Value of 22.75, an EV to Sales ratio of 337.66, and a negative ROE of -345.95%. In comparison, Journey Medical Corp. has a P/E of -18.6994 and Fortress Biotech, Inc. has a P/E of -1.1589, both indicating that Checkpoint is not competitively positioned within its peer group.<BR><BR>Despite the overvaluation, Checkpoint Therapeutics has shown strong short-term performance, with a year-to-date return of 33.12%, significantly outperforming the S&P 500's 12.22%. However, the long-term outlook remains concerning, as the company has experienced a staggering -79.91% return over the past five years compared to the S&P 500's 96.61%.

Read More

Is Checkpoint Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of April 14, 2025, Checkpoint Therapeutics, Inc. has a bullish trend supported by strong technical indicators, outperforming the S&P 500 with a year-to-date return of 33.12% compared to 12.22% and a one-year return of 132.79% versus 17.14%.

As of 14 April 2025, the technical trend for Checkpoint Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD, Bollinger Bands, KST, and OBV are all bullish, while the daily moving averages also confirm a bullish trend. The Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 33.12% compared to the S&P 500's 12.22%, and a one-year return of 132.79% versus 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 371 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

23.88%

stock-summary
Debt Equity

-2.03

stock-summary
Return on Equity

-345.95%

stock-summary
Price to Book

22.75

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
48.95%
0%
48.95%
6 Months
-2.96%
0%
-2.96%
1 Year
132.79%
0%
132.79%
2 Years
58.36%
0%
58.36%
3 Years
-69.79%
0%
-69.79%
4 Years
-84.1%
0%
-84.1%
5 Years
-79.91%
0%
-79.91%

Checkpoint Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Checkpoint Therapeutics, Inc. technically bullish or bearish?

As of 14 April 2025, the technical trend for Checkpoint Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD, Bollinger Bands, KST, and OBV are all bullish, while the daily moving averages also confirm a bullish trend. The Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. In terms of performance, the stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 33.12% compared to the S&P 500's 12.22%, and a one-year return of 132.79% versus 17.14%....

Read More

Is Checkpoint Therapeutics, Inc. overvalued or undervalued?

As of 6 May 2021, the valuation grade for Checkpoint Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its high Price to Book Value of 22.75, an EV to Sales ratio of 337.66, and a negative ROE of -345.95%. In comparison, Journey Medical Corp. has a P/E of -18.6994 and Fortress Biotech, Inc. has a P/E of -1.1589, both indicating that Checkpoint is not competitively positioned within its peer group. Despite the overvaluation, Checkpoint Therapeutics has shown strong short-term performance, with a year-to-date return of 33.12%, significantly outperforming the S&P 500's 12.22%. However, the long-term outlook remains concerning, as the company has experienced a staggering -79.91% return over the past five years compared to the S&P 500's 96.61%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-55.65%
EBIT Growth (5y)
-188.17%
EBIT to Interest (avg)
-49.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.03
Sales to Capital Employed (avg)
-0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
79.03%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
22.75
EV to EBIT
-5.99
EV to EBITDA
-5.99
EV to Capital Employed
-20.16
EV to Sales
337.66
PEG Ratio
NA
Dividend Yield
23.88%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-345.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 6 Schemes (5.86%)

Foreign Institutions

Held by 21 Foreign Institutions (7.13%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 61.25% vs -197.94% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.10",
          "val2": "-28.80",
          "chgp": "61.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "-28.90",
          "chgp": "61.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.49% vs 17.25% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-56.20",
          "val2": "-52.10",
          "chgp": "-7.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.20",
          "chgp": "-150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-56.20",
          "val2": "-51.80",
          "chgp": "-8.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,370,097.60%",
          "val2": "-506,291.30%",
          "chgp": "-86,380.63%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.10
-28.80
61.46%
Interest
0.00
0.00
Exceptional Items
-0.10
-0.10
Consolidate Net Profit
-11.20
-28.90
61.25%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 61.25% vs -197.94% in Dec 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-56.20
-52.10
-7.87%
Interest
0.00
0.00
Exceptional Items
-0.10
0.20
-150.00%
Consolidate Net Profit
-56.20
-51.80
-8.49%
Operating Profit Margin (Excl OI)
-1,370,097.60%
-506,291.30%
-86,380.63%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.49% vs 17.25% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Checkpoint Therapeutics, Inc. stock-summary
stock-summary
Checkpoint Therapeutics, Inc.
Pharmaceuticals: Major
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Company Coordinates stock-summary
Company Details
2 Gansevoort St Fl 9 , NEW YORK NY : 10014-1667
stock-summary
Tel: 1 212 5544366
stock-summary
http://www.checkpointtx.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."